| Expression pattern: |
UP |
| Associated gene: |
WNT2, HNRNPL, GLS, beta-catenin, phosphorylated beta-catenin (p-beta-catenin), MMP9 |
| Associated microRNA: |
miR-30a-3p |
| Biological function: |
promotes proliferation, migration, invasion, EMT, tumor growth and metastasis; promotes glutamine metabolism; inhibits ROS production |
| Molecular mechanism: |
Acts as a ceRNA/miRNA sponge for miR-30a-3p to relieve inhibition of WNT2 and activate WNT2/beta-catenin signaling; HNRNPL binds flanking introns to promote circLMO7 cyclization; promotes glutaminolysis via GLS and related metabolites |
| Biological pathway or process: |
Wnt/beta-catenin (promotes); proliferation (promotes); migration (promotes); invasion (promotes); metastasis (promotes); EMT (promotes); glutaminolysis (promotes); oxidative phosphorylation (other); mitochondrial function (other); ceRNA regulation (promotes) |
| Detected method: |
Q
S
|
| Validation methods: |
RNA-seq; RT-qPCR; Sanger Sequencing; FISH / smFISH; RNase R Treatment; divergent primers PCR; Actinomycin D / DRB Stability Assay; RNA Pull-Down; Luciferase Reporter Assay; Transfection; Colony Formation Assay; EdU Staining; Transwell Assay; Western Blot; IF (Immunofluorescence); RIP (RNA Immunoprecipitation); In Vivo Animal Model; H&E Staining; Bioinformatics Analysis; Clinical Sample Validation; IHC (Immunohistochemistry) |
| Clinical significance: |
circLMO7 expression was closely related to the T grade and stage of GC; expected to become a new biomarker for GC |
| Description: |
circLMO7 (hsa_circ_0008259), derived from LMO7, is upregulated in gastric cancer and mainly localizes to the cytoplasm. It promotes GC proliferation, migration/invasion, EMT and in vivo tumor growth/metastasis by sponging miR-30a-3p to derepress WNT2 and activate WNT2/beta-catenin signaling, and it enhances glutaminolysis (via GLS-related metabolic changes). HNRNPL facilitates circLMO7 biogenesis by binding to flanking introns. |
| Confidence score: |
0.8794 |